TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14578911
Drug: BILN 2061,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BILN 2061, a small molecule NS3 protease inhibitor administered orally for 2 days
Study: 4061965
Drug: Pyridostigmine (sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (sustained-release form)
Study: 29895931
Drug: Weight-based (WB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based (WB) plerixafor 0.24 mg/kg
Study: 29895931
Drug: Fixed-dose (FD)
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose (FD) plerixafor 20 mg
Study: 24359044
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg of paracetamol via intravenous infusion (Group II)
Study: 12122552
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g lycasin HBC
Study: 12122552
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g isomalt
Study: 12122552
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g isomalt
Study: 12122552
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g lycasin HBC
Study: 1693733
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER tablets 10 mg once daily (n = 50)
Study: 1693733
Drug: Plain tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain tablets 5 mg twice daily (n = 52)
Study: 582722
Drug: i.v. cefazedone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. cefazedone 500 mg
Study: 582722
Drug: i.v. cefazedone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. cefazedone 1000 mg
Study: 582722
Drug: i.m. cefazedone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. cefazedone 500 mg
Study: 582722
Drug: cefazolin 1000
Normalized name: cefazolin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cefazolin 1000 mg
Study: 582722
Drug: cefazolin 500
Normalized name: cefazolin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cefazolin 500 mg
Study: 26690199
Drug: baseline HIV-1
Normalized name: petrolatum 1 MG/MG [Vaseline]
Approvals — FDA: no, EMA: no, PMDA: no
Description: baseline HIV-1 RNA >100,000 copies/mL
Study: 21147813
Drug: Relaxation training
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation training according to Yoga In Daily Life(®) system
Study: 18310964
Drug: delapril 30
Normalized name: Delapril
DrugBank: Delapril (DB13312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: delapril 30 mg/manidipine 10 mg combination
Study: 18310964
Drug: olmesartan 20
Normalized name: olmesartan 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: olmesartan 20 mg/HCTZ 12.5 mg combination
Study: 17518172
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of remifentanil plus morphine and nonsteroidal anti-inflammatory drugs
Study: 19799882
Drug: Acamprosate (1998
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate (1998 mg/day)
Study: 17989696
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (inhaled oxygen placebo only)
Study: 19841125
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) therapy
Study: 9895043
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg t.i.d. for 3 days
Study: 9166505
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg oral granisetron HCI twice a day for 7 days
Study: 1901104
Drug: Intravenous medium-chain
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous medium-chain triglycerides (MCT)
Study: 1901104
Drug: Intravenous long-chain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous long-chain triglycerides (LCT)
Study: 30922814
Drug: CNSA-001 (sepiapterin)
Normalized name: Sepiapterin
DrugBank: Sepiapterin (DB16326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNSA-001 (sepiapterin) 5, 20 or 60 mg/kg (repeat daily dosing)
Study: 23444761
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (400 microg every four hours, up to three doses)
Study: 23444761
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (400 microg every four hours, up to three doses)
Study: 23444761
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (600 microg primary dosage)
Study: 23444761
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (600 microg primary dosage) and continuation of oral dose
Study: 19006526
Drug: Organized weekly
Normalized name: Organic germanium
DrugBank: Propagermanium (DB17608)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organized weekly exercise for 13 weeks
Study: 14501621
Drug: Mosapride 60
Normalized name: mosapride
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride 60 mg twice daily
Study: 14501621
Drug: Mosapride 30
Normalized name: mosapride
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride 30 mg three times daily
Study: 10463897
Drug: Cisapride 20
Normalized name: cisapride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 20 mg twice daily
Study: 3421202
Drug: 272 g
Normalized name: SODIUM FLUORIDE 0.0272 g in 1 g DENTAL AEROSOL, FOAM [PCXX LIME APF F]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 272 g cooked carrots
Study: 22686292
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg once daily for 6 months
Study: 21654733
Drug: CC/CT genotypes
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC/CT genotypes of the FKBP5 gene SNP rs1360780
Study: 18985059
Drug: Psyllium (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium (3.0 to 20.4 g per day)
Study: 12761949
Drug: Regional intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Regional intra-arterial chemotherapy (IACT)
Study: 12761949
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy (SCT)
Study: 30170329
Drug: Pregabalin (75-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (75-600 mg/day)
Study: 26931509
Drug: Energy drink
Normalized name: Boost Energy Drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy drink (2 mg caffeine per kg body weight; low dose)
Study: 26931509
Drug: Energy drink
Normalized name: Boost Energy Drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy drink (3 mg caffeine per kg body weight; medium dose)
Study: 26931509
Drug: Coffee (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee (2 mg caffeine per kg body weight)
Study: 26931509
Drug: 250 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml water
Study: 16087057
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n = 25)
Study: 18653326
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate (two doses)
Study: 12924702
Drug: Aprotinin (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (240 mg/m2 administered intravenously over 20 minutes, followed by infusions of 56 mg/m2/hr)
Study: 2689183
Drug: Clonazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (2 mg)
Study: 1353708
Drug: Esmolol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (500 micrograms.kg‐1 i.v. bolus followed by 150‐300 micrograms.kg‐1.min‐1 maintenance infusion)
Study: 1353708
Drug: Labetalol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (5 mg i.v. bolus followed by 5 mg increments as needed up to a maximum of 1 mg.kg‐1)
Study: 6337524
Drug: Extradural diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural diamorphine 0.1 mg/kg
Study: 6337524
Drug: Intramuscular diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular diamorphine 0.1 mg/kg
Study: 29475804
Drug: Tenofovir alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir alafenamide (10 mg or 25 mg) plus emtricitabine (200 mg)
Study: 29475804
Drug: Abacavir (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir (600 mg) plus lamivudine (300 mg)
Study: 17805089
Drug: Quercetin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (1000 mg.d(‐1))
Study: 11133794
Drug: IVIg (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg (500 mg/kg/day for 5 consecutive days, once a month for 3 months)
Study: 7518629
Drug: 0.0005% iloprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0005% iloprost solution
Study: 30980539
Drug: Metformin at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin at baseline
Study: 30980539
Drug: Metformin during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin during concomitant radiochemotherapy (TMZ/RT)
Study: 30980539
Drug: Metformin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin monotherapy at baseline
Study: 30980539
Drug: Metformin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin monotherapy during TMZ/RT
Study: 14635083
Drug: Palonosetron 0.25
Normalized name: palonosetron 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.25 mg
Study: 8829860
Drug: Granisetron 3
Normalized name: granisetron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 3 mg
Study: 21496149
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin
Study: 9064945
Drug: Quinaprilat (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinaprilat (low dose: 0.5 and 1.0 mg, medium dose: 1.0 and 2.5 mg, high dose: 5.0 and 10.0 mg)
Study: 1591513
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg i.v. cocaine injections
Study: 8863695
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (60 mg)
Study: 28698321
Drug: oral oseltamivir
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral oseltamivir plus inhaled zanamivir (arm OZ)
Study: 28698321
Drug: oral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral therapy
Study: 28698321
Drug: inhaled therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled therapy
Study: 28698321
Drug: antibiotic coprescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibiotic coprescriptions
Study: 28698321
Drug: active combination
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: active combination treatment
Study: 23406672
Drug: Sildenafil 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 40 mg thrice daily
Study: 17309402
Drug: High density
Normalized name: High density lipoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High density lipoprotein cholesterol level < 1.0 mmol/L
Study: 15121405
Drug: Olpadronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olpadronate (10 mg/m2 daily)
Study: 31035354
Drug: Protein-fortified diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-fortified diet (1.8 g/kg/day)
Study: 21741011
Drug: DTPa-IPV/Hib vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa-IPV/Hib vaccine co-administered with hepatitis B vaccine
Study: 17075318
Drug: Gemcitabine (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1500 mg/m) as a 30‐min intravenous infusion on days 1 and 8, followed by oxaliplatin (130 mg/m) as a 4‐h intravenous infusion on day 8 every 21 days
Study: 7691117
Drug: Epirubicin 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 75 mg/m2 with G-CSF
Study: 7691117
Drug: Epirubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 60 mg/m2 without G-CSF
Study: 7691117
Drug: Epirubicin 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 90 mg/m2 with G-CSF
Study: 6818829
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol with digital ocular compression
Study: 6818829
Drug: Combined acetazolamide-mannitol
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined acetazolamide-mannitol pre-medication with digital compression
Study: 2817305
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no injections)
Study: 1826962
Drug: etanidazole (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: etanidazole (2.0 g/m2) and pimonidazole (0.75 g/m2)
Study: 1826962
Drug: etanidazole (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: etanidazole (2.0 g/m2/dose) and pimonidazole (0.75 g/m2)
Study: 29566740
Drug: Filgotinib 50
Normalized name: nilotinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgotinib 50 mg
Study: 21704239
Drug: CER 30
Normalized name: CER-001
DrugBank: CER-001 (DB18538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CER 30 mg once daily
Study: 21704239
Drug: CIR 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIR 10 mg TID
Study: 1592065
Drug: Caffeine (Caf)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (Caf) 250 mg
Study: 20575654
Drug: Natural progesterone
Normalized name: NATURAL PROGESTERONE CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural progesterone (NP) per vagina at 100 mg/day
Study: 20575654
Drug: Natural progesterone
Normalized name: NATURAL PROGESTERONE CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural progesterone (NP) per vagina at 200 mg/day
Study: 20575654
Drug: Natural progesterone
Normalized name: NATURAL PROGESTERONE CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural progesterone (NP) per os at 100 mg/day
Study: 20575654
Drug: Natural progesterone
Normalized name: NATURAL PROGESTERONE CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural progesterone (NP) per os at 200 mg/day
Study: 16547380
Drug: Standard amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard amino acid solution with glutamine dipeptide (20% of total amino acids)
Study: 3079994
Drug: Standard amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard amino acid solution
Study: 11465341
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone replacement (1 to 2 U GH/day) for 6 months, followed by 2 U GH/day for an additional 6 months.
Study: 3395542
Drug: MST 60
Normalized name: MST 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: MST 60 mg and hyoscine 0.6 mg
Study: 28617566
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-Acetylcysteine (NAC) 3,000 mg daily
Study: 21527594
Drug: Oral synbiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral synbiotics (Bifidobacterium, Lactobacillus, and galactooligosaccharides) preoperatively for 14 days and postoperatively for 11 days
Study: 18467280
Drug: Exercise with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise with prophylactic EPO therapy
Study: 12953793
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of HCA
Study: 8892452
Drug: 30 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 Gy total dose extended field radiotherapy (EF‐RT) plus 10 Gy total dose involved field radiotherapy (IF‐RT)
Study: 3902531
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg once daily
Study: 29776112
Drug: Tensor renormalization
Normalized name: aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tensor renormalization group algorithm with randomized singular value decomposition; specific details on dosage and duration not applicable.
Study: 24035407
Drug: Risperidone (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (target dose 1.5 mg)
Study: 22911284
Drug: Group Exercise
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Exercise Program (GI) - strength, balance, and functional mobility exercises, 50 minutes, twice a week for 4 months
Study: 22911284
Drug: Stretching Exercises
Normalized name: Mederma Stretch Mark Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stretching Exercises (GC) - 50 minutes, twice a week for 4 months
Study: 20856886
Drug: Reduction in
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction in plasma HIV-1 RNA by 0.74 log(10) copies/mL
Study: 20856886
Drug: Baseline plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline plasma HIV-1 levels ≥4 log(10) copies/mL
Study: 12581050
Drug: Intravenous pyelography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pyelography (IVP)
Study: 12690415
Drug: 131I-lipiodol therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 131I-lipiodol therapy with a mean activity of 1.9 GBq (SD 0.2)
Study: 12690415
Drug: 131I-lipiodol therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 131I-lipiodol therapy with potassium iodide (KI) thyroid blocking
Study: 12690415
Drug: Biological dosimetry
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological dosimetry using the in vitro micronucleus (MN) assay
Study: 8946272
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg dexfenfluramine twice daily
Study: 2014076
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (PGE2) 3‐mg pessaries 4 hours apart, followed by oxytocin infusion if necessary
Study: 25181622
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin infusion
Study: 6368424
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rifampin (RMP) 600 mg and ethionamide (ETH) 500 mg
Study: 6368424
Drug: RMP administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: RMP administered twice a week for three months
Study: 6368424
Drug: Reduction of
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction of daily dose of ETH or reduction of duration of RMP + ETH
Study: 27484673
Drug: 1064-nm laser
Normalized name: aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1064-nm laser treatment
Study: 8758083
Drug: Chloroquine (CHL)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CHL) 25 mg/kg over 3 days
Study: 8758083
Drug: Sulfadoxine (SDX)
Normalized name: Sulfadoxine
DrugBank: Sulfadoxine (DB01299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfadoxine (SDX) 25 mg/kg plus Pyrimethamine (PYR) 1.25 mg/kg (statim dose)
Study: 29605216
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS)
Study: 31744837
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) with longer time (>4 years) since initiation
Study: 31744837
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) with higher mean daily dose (>1000 μg fluticasone equivalents)
Study: 27797683
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) 500 mg daily for 4 weeks
Study: 26029855
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa oil (3 g per day, 1 g before each meal) with a low-calorie diet
Study: 21442805
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment in the control group (20 cases)
Study: 11929402
Drug: Celecoxib (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (800 mg/day)
Study: 9390588
Drug: Nicardipine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 0.5 mg
Study: 7910722
Drug: GLQ223 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLQ223 administered intravenously at doses of 36 and 50 micrograms/kg
Study: 7910722
Drug: GLQ223 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLQ223 administered intravenously at doses of 8, 16, 24, 36, and 50 micrograms/kg
Study: 7910722
Drug: GLQ223 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLQ223 administered intravenously
Study: 31578080
Drug: Lp(a) lowering
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lp(a) lowering by 50 mg/dL (105 nmol/L) for 5 years
Study: 31578080
Drug: Lp(a) lowering
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lp(a) lowering by 99 mg/dL (212 nmol/L) for 5 years
Study: 31578080
Drug: Individuals with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individuals with Lp(a) 10 to 49 mg/dL (18-104 nmol/L)
Study: 14586387
Drug: Cigarette smoking
Normalized name: Cigarette smoking tobacco
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarette smoking (7 days, 250 mg chlorzoxazone and 250 mg caffeine)